癌症研究
无意义介导的衰变
突变
遗传学
突变体
移码突变
分子生物学
外显子
选择性拼接
RNA结合蛋白
癌症
作者
Abigael Cheruiyot,Shan Li,Sridhar Nonavinkere Srivatsan,Tanzir Ahmed,Yuhao Chen,Delphine Lemaçon,Ying Li,Zheng Yang,Brian A. Wadugu,Wayne A. Warner,Shondra M. Pruett-Miller,Esther A. Obeng,Daniel C. Link,Dalin He,Fei Xiao,Xiaowei Wang,Julie M. Bailis,Matthew J. Walter,Zhongsheng You
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2021-07-02
卷期号:81 (17): 4499-4513
被引量:2
标识
DOI:10.1158/0008-5472.can-20-4016
摘要
Nonsense-mediated RNA decay (NMD) is recognized as an RNA surveillance pathway that targets aberrant mRNAs with premature translation termination codons (PTC) for degradation, however, its molecular mechanisms and roles in health and disease remain incompletely understood. In this study, we developed a novel reporter system to accurately measure NMD activity in individual cells. A genome-wide CRISPR-Cas9 knockout screen using this reporter system identified novel NMD-promoting factors, including multiple components of the SF3B complex and other U2 spliceosome factors. Interestingly, cells with mutations in the spliceosome genes SF3B1 and U2AF1, which are commonly found in myelodysplastic syndrome (MDS) and cancers, have overall attenuated NMD activity. Compared with wild-type (WT) cells, SF3B1- and U2AF1-mutant cells were more sensitive to NMD inhibition, a phenotype that is accompanied by elevated DNA replication obstruction, DNA damage, and chromosomal instability. Remarkably, the sensitivity of spliceosome mutant cells to NMD inhibition was rescued by overexpression of RNase H1, which removes R-loops in the genome. Together, these findings shed new light on the functional interplay between NMD and RNA splicing and suggest a novel synthetic lethal strategy for the treatment of MDS and cancers with spliceosome mutations. SIGNIFICANCE: This study has developed a novel NMD reporter system and identified a potential therapeutic approach of targeting the NMD pathway to treat cancer with spliceosome gene mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI